Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael Monuteaux, Sc.D.

Co-Author

This page shows the publications co-authored by Michael Monuteaux and Timothy Wilens.
Connection Strength

1.864
  1. Further evidence of an association between adolescent bipolar disorder with smoking and substance use disorders: a controlled study. Drug Alcohol Depend. 2008 Jun 01; 95(3):188-98.
    View in: PubMed
    Score: 0.387
  2. Can adults with attention-deficit/hyperactivity disorder be distinguished from those with comorbid bipolar disorder? Findings from a sample of clinically referred adults. Biol Psychiatry. 2003 Jul 01; 54(1):1-8.
    View in: PubMed
    Score: 0.279
  3. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008 Oct; 162(10):916-21.
    View in: PubMed
    Score: 0.100
  4. The familial association between cigarette smoking and ADHD: a study of clinically referred girls with and without ADHD, and their families. Nicotine Tob Res. 2008 Oct; 10(10):1549-58.
    View in: PubMed
    Score: 0.100
  5. Does social class predict substance problems in young adults with ADHD? Am J Addict. 2007 Sep-Oct; 16(5):403-9.
    View in: PubMed
    Score: 0.093
  6. Association of bipolar and substance use disorders in parents of adolescents with bipolar disorder. Biol Psychiatry. 2007 Jul 15; 62(2):129-34.
    View in: PubMed
    Score: 0.091
  7. Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD. Am J Addict. 2007; 16 Suppl 1:14-21; quiz 22-3.
    View in: PubMed
    Score: 0.089
  8. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006 Apr; 45(4):408-14.
    View in: PubMed
    Score: 0.084
  9. The clinical dilemma of using medications in substance-abusing adolescents and adults with attention-deficit/hyperactivity disorder: what does the literature tell us? J Child Adolesc Psychopharmacol. 2005 Oct; 15(5):787-98.
    View in: PubMed
    Score: 0.082
  10. Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD. J Am Acad Child Adolesc Psychiatry. 2002 Mar; 41(3):262-8.
    View in: PubMed
    Score: 0.064
  11. Patterns of psychopathology and dysfunction in clinically referred preschoolers. J Dev Behav Pediatr. 2002 Feb; 23(1 Suppl):S31-6.
    View in: PubMed
    Score: 0.063
  12. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001 Feb; 158(2):282-8.
    View in: PubMed
    Score: 0.059
  13. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1999 Dec; 156(12):1931-7.
    View in: PubMed
    Score: 0.054
  14. Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry. 2010 Apr; 167(4):409-17.
    View in: PubMed
    Score: 0.027
  15. Prescribing patterns for treatment of pediatric bipolar disorder in a specialty clinic. J Child Adolesc Psychopharmacol. 2009 Oct; 19(5):529-38.
    View in: PubMed
    Score: 0.027
  16. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics. 2009 Jul; 124(1):71-8.
    View in: PubMed
    Score: 0.026
  17. Examination of concordance between maternal and youth reports in the diagnosis of pediatric bipolar disorder. Bipolar Disord. 2009 May; 11(3):298-306.
    View in: PubMed
    Score: 0.026
  18. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008 May; 165(5):597-603.
    View in: PubMed
    Score: 0.024
  19. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry. 2008 Jan; 165(1):107-15.
    View in: PubMed
    Score: 0.024
  20. Familial transmission of derived phenotypes for molecular genetic studies of substance use disorders. Drug Alcohol Depend. 2008 Jan 01; 92(1-3):100-7.
    View in: PubMed
    Score: 0.023
  21. Deriving phenotypes for molecular genetic studies of substance use disorders: a family study approach. Drug Alcohol Depend. 2007 May 11; 88(2-3):244-50.
    View in: PubMed
    Score: 0.022
  22. Psychopathology in females with attention-deficit/hyperactivity disorder: a controlled, five-year prospective study. Biol Psychiatry. 2006 Nov 15; 60(10):1098-105.
    View in: PubMed
    Score: 0.021
  23. Family based association analysis of statistically derived quantitative traits for drug use in ADHD and the dopamine transporter gene. Addict Behav. 2006 Jun; 31(6):1088-99.
    View in: PubMed
    Score: 0.021
  24. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med. 2006 Feb; 36(2):167-79.
    View in: PubMed
    Score: 0.021
  25. Is cigarette smoking a gateway to alcohol and illicit drug use disorders? A study of youths with and without attention deficit hyperactivity disorder. Biol Psychiatry. 2006 Feb 01; 59(3):258-64.
    View in: PubMed
    Score: 0.020
  26. Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol. 2004 Oct; 72(5):757-66.
    View in: PubMed
    Score: 0.019
  27. Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial. J Child Adolesc Psychopharmacol. 2000; 10(3):205-16.
    View in: PubMed
    Score: 0.014
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.